



# SHUKRA

PHARMACEUTICALS LTD.

Ref No: - SHUKRAPHAR/SEC/STOCK/2024-25

Date: 14/11/2024

To,  
Department of Corporate Services,  
BSE Limited,  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort,  
Mumbai - 400 001.

SECURITY CODE: 524632 || SECURITY ID: SHUKRAPHAR || ISIN: INE551C01028 || SERIES: EQ

Dear Sir/Madam,

**Sub.:- Outcome of Board Meeting held today i.e. on 14<sup>th</sup> November, 2024 and submission of Un-audited Financial Results of the Company for the Second Quarter and Half Year ended on 30<sup>th</sup> September, 2024.**

With reference to our previous communications through letter dated 07<sup>th</sup> November, 2024 regarding the date of Board Meeting and business to be transacted thereat etc., and in continuation to the same, this is to inform you that the Meeting of Board of Directors commenced at 3.15 p.m. today and has inter alia considered the following:

1. Pursuant to review and recommendation of Audit Committee of the Company the Board has considered and approved Un-audited Financial Results of the Company along with Limited Review Report for the second quarter and half year ended on 30<sup>th</sup> September, 2024 of the current financial year 2024-25, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations").
2. Pursuant to review and recommendation of Audit Committee of the Company the Board has considered and reviewed the related party transactions taken place during the half year ended on 30<sup>th</sup> September, 2024 and the same be filed with the stock exchange in pursuance to the requirement of Regulation 23 of SEBI LODR Regulations.

The meeting of the Board of Directors concluded at 5.05 p.m.

You are therefore requested to take note of the same.

Thanking you,

Yours faithfully,

For, Shukra Pharmaceuticals Limited



Dakshesh Rameshchandra Shah  
Chairman & Managing Director  
DIN: 00561666

**CIN : L24231GJ1993PLC019079**

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.  
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar-382721, Gujarat, India, Ph. : 02764-286317

**SHUKRA PHARMACEUTICALS LIMITED**

CIN: L24231GJ1993PLC019079

3rd Floor, Dev House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380003

Email : info@shukrapharmaceuticals.com

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2024**

(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Sr. No.	Particulars	QUARTER ENDED			HALF YEARLY		Year Ended
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
<b>1</b>	<b>Income from Operations</b>						
I	Revenue from Operations	555.52	317.80	2,463.83	873.32	4,479.84	7,457.29
	<b>(a) Net Sales/ Income from Operations</b>	<b>555.52</b>	<b>317.80</b>	<b>2,463.83</b>	<b>873.32</b>	<b>4,479.84</b>	<b>7,457.29</b>
II	Other Income	101.74	71.76	24.25	173.50	87.61	281.52
	<b>Total Income from Operations (I+II)</b>	<b>657.27</b>	<b>389.56</b>	<b>2,488.08</b>	<b>1,046.83</b>	<b>4,567.45</b>	<b>7,738.81</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	145.19	92.15	479.63	237.34	682.26	1,337.97
	(b) Purchase of Stock-in Trade	86.28	-	1,093.94	86.28	2,697.91	3,040.52
	(c) Changes in inventories of finished goods, and work-in-progress and stock in trade	6.35	(90.48)	194.20	(84.13)	178.62	70.15
	(d) Employee Benefit Expenses	142.90	138.27	137.10	281.17	271.55	564.72
	(e) Finance Cost	11.11	6.17	6.49	17.28	14.95	28.50
	(f) Depreciation & Amortisation Expenses	69.82	66.51	56.17	136.33	102.11	205.02
	(g) Other Expenses	108.12	97.27	50.17	205.39	107.01	503.60
	<b>Total Expenses</b>	<b>569.78</b>	<b>309.89</b>	<b>2,017.70</b>	<b>879.67</b>	<b>4,054.41</b>	<b>5,750.47</b>
<b>3</b>	<b>Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2)</b>	<b>87.49</b>	<b>79.67</b>	<b>470.38</b>	<b>167.16</b>	<b>513.04</b>	<b>1,988.34</b>
<b>4</b>	Exceptional Items	-	-	-	-	-	-
<b>5</b>	<b>Profit / (Loss) before Extra ordinary items and Tax (3-4)</b>	<b>87.49</b>	<b>79.67</b>	<b>470.38</b>	<b>167.16</b>	<b>513.04</b>	<b>1,988.34</b>
<b>6</b>	Extra ordinary items	-	-	-	-	-	-
<b>7</b>	<b>Net Profit / (Loss) from Ordinary Activities before Tax(5-6)</b>	<b>87.49</b>	<b>79.67</b>	<b>470.38</b>	<b>167.16</b>	<b>513.04</b>	<b>1,988.34</b>
<b>8</b>	<b>Tax Expenses</b>						
	I. Current Tax	28.80	26.60	-	55.40	-	136.16
	II. Deferred Tax	4.80	4.54	(0.78)	9.34	(0.14)	(1.55)
	II. Tax of Earlier Year	-	-	0.23	-	0.23	-
	IV. MAT Credit Entitlement	-	-	-	-	-	-
<b>9</b>	<b>Net Profit / (Loss) for the Period (7-8)</b>	<b>53.89</b>	<b>48.53</b>	<b>470.93</b>	<b>102.42</b>	<b>512.95</b>	<b>1,853.73</b>
<b>10</b>	<b>Other Comprehensive Income (net off Tax)</b>						
	Remeasurement of defined benefit plans	-	-	-	-	-	-
	Prior Period Adjustments & Expenses	-	-	-	-	-	-
<b>11</b>	<b>Total Comprehensive Income for the period (9+10)</b>	<b>53.89</b>	<b>48.53</b>	<b>470.93</b>	<b>102.42</b>	<b>512.95</b>	<b>1,853.73</b>
<b>12</b>	<b>Paid up Equity Share Capital</b>	<b>4,378.79</b>	<b>4,378.79</b>	<b>1,086.45</b>	<b>4,378.79</b>	<b>1,086.45</b>	<b>1,094.70</b>
<b>13</b>	Face Value of Equity Shares	10.00	10.00	10.00	10.00	10.00	10.00
<b>14</b>	Earnings per Share (of Re. 10/- each ) :						
	(a) Basic-Rs	0.25	0.11	1.47	0.25	2.93	16.93

<b>(b) Diluted-Rs</b>	<b>0.25</b>	<b>0.11</b>	<b>1.47</b>	<b>0.25</b>	<b>2.93</b>	<b>16.93</b>
-----------------------	-------------	-------------	-------------	-------------	-------------	--------------

**NOTES:**

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 14th November, 2024. The statutory auditors have carried out review of the results for the quarter ended on 30th September, 2024 and have expressed an unqualified audit opinion.
2. The Unaudited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015.
3. The Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. [www.bseindia.com](http://www.bseindia.com), where the Shares of the Company are listed.
4. During the quarter ended 30th September, 2024, 2 complaints were received out of that 2 complaints were disposed off at the end of the quarter.
5. The figures for the previous period/year have been regrouped /reclassified, wherever necessary.
6. The Company is operating in single segment, so above results are for single segment only.

**For and on behalf of Board of Directors of  
SHUKRA PHARMACEUTICALS LIMITED**

**Place: Ahmedabad  
Date: 14-11-2024**

**Bhoomiben Patel  
Director  
(DIN : 08316893)**

**SHUKRA PHARMACEUTICALS LIMITED**

CIN:L24231GJ1993PLC019079

Unaudited Standalone Balance Sheet as at September 30, 2024

(All amounts in ₹ Lakhs, Unless Otherwise Stated)

Particulars	As at September 30, 2024	As at March 31, 2024
<b>Assets</b>		
<b>Non-current assets</b>		
Property, plant and equipment	1,968.72	1,994.28
Capital work-in-progress	166.17	166.17
	<b>2,134.89</b>	<b>2,160.45</b>
<b>Current assets</b>		
Inventories	444.55	231.44
Financial assets		
(i) Trade receivables	401.90	2,451.29
(iii) Loans	240.85	197.90
(ii) Bank balance other than cash and cash equivalents	1,803.43	998.04
Income tax assets (Assets)	39.84	34.11
Other current assets	3,001.22	1,710.48
	<b>5,931.78</b>	<b>5,623.26</b>
<b>Total Assets</b>	<b>8,066.68</b>	<b>7,783.71</b>
<b>Equity and liabilities</b>		
<b>Equity</b>		
Equity share capital	4,378.79	1,094.70
Other equity	1,049.73	4,669.26
	<b>5,428.52</b>	<b>5,763.96</b>
<b>Total Equity</b>	<b>5,428.52</b>	<b>5,763.96</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
(i) Borrowings	220.97	265.67
Deferred tax liabilities (net)	336.60	327.27
Provisions	13.53	11.48
	<b>571.11</b>	<b>604.42</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Borrowings	51.52	49.72
(ii) Trade payables	850.63	722.14
Other current liabilities	1,039.90	564.74
Provisions	125.00	78.72
	<b>2,067.05</b>	<b>1,415.32</b>
<b>Total liabilities</b>	<b>2,638.16</b>	<b>2,019.74</b>
<b>Total equity and liabilities</b>	<b>8,066.68</b>	<b>7,783.71</b>

For and on behalf of Board of Directors of  
SHUKRA PHARMACEUTICALS LIMITEDPlace: Ahmedabad  
Date: 14-11-2024Bhoomiben Patel  
Director  
(DIN : 08316893)

**SHUKRA PHARMACEUTICALS LIMITED**

**CIN:L24231GJ1993PLC019079**

**Statement of Unaudited Cash Flows for the Half year ended September 30, 2024**

**(All amounts in ₹ Lakhs, Unless Otherwise Stated)**

Particulars	For the half year ended September 30, 2024	For the half year ended September 30, 2023
<b>Cash flow from operating activities</b>		
<b>Profit before tax as per statement of profit and loss</b>	167.17	513.04
Adjustments for:		
Depreciation and amortisation	136.33	102.11
Interest income	(54.66)	(2.49)
Interest expense	17.28	14.95
Sundry Balances Written back	(0.09)	(24.94)
<b>Operating profit before working capital changes</b>	<b>266.03</b>	<b>602.67</b>
Movements in working capital :		
(Increase)/decrease in trade receivables	2,049.39	191.87
(Increase)/decrease in inventories	(213.11)	282.43
(Increase)/decrease in other assets	(1,339.42)	134.80
Increase/(decrease) in trade payables	128.58	(2,845.13)
Increase/(decrease) in other liabilities	479.01	1,108.13
<b>Cash generated from operations</b>	<b>1,370.47</b>	<b>(525.23)</b>
Direct taxes (paid)/refund (net)	(9.11)	(5.85)
<b>Net cash Inflow / (Outflow) from operating activities (A)</b>	<b>1,361.36</b>	<b>(531.08)</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipments (Including capital work in progress, capital advances and capital creditors)	(110.77)	(102.35)
Interest received	54.66	2.49
<b>Net cash inflow from investing activities (B)</b>	<b>(56.11)</b>	<b>(99.86)</b>
<b>Cash flows from financing activities</b>		
Proceeds/(Repayment) of long-term borrowing	(44.70)	(188.03)
Interest paid	(17.28)	(14.95)
Proceeds from issuance of shares during the period	-	1,375.22
Dividend paid	(437.88)	-
<b>Net cash Inflow from financing activities (C)</b>	<b>(499.86)</b>	<b>1,172.24</b>
<b>Net increase / (decrease) in cash &amp; cash equivalents (A + B + C)</b>	<b>805.39</b>	<b>541.30</b>
Cash and cash equivalents at the beginning of the year	998.04	397.31
<b>Cash and cash equivalents at the end of the period</b>	<b>1,803.43</b>	<b>938.61</b>
<b>Notes:</b>		
Component of cash and cash equivalents		
Cash on hand	31.75	5.87
On current accounts	35.85	932.74
In fixed deposit	1,735.83	-
<b>Cash and Cash Equivalents at the End of the period</b>	<b>1,803.43</b>	<b>938.61</b>

**Note:**

(1) The Statement of Cash flows has been prepared under the Indirect method as set out in Ind AS 7 – Statement of Cash flows notified under section 133 of The Companies Act, 2013, read together with paragraph 7 of the Companies (Indian Accounting Standard) Rules 2015 (as amended).

**For and on behalf of Board of Directors of  
SHUKRA PHARMACEUTICALS LIMITED**

Place: Ahmedabad  
Date: 14-11-2024

Bhoomiben Patel  
Director  
(DIN : 08316893)



INDEPENDENT AUDITOR'S REVIEW REPORT on Standalone Unaudited Quarterly and half yearly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,  
The Board of Directors,  
SHUKRA PHARMACEUTICALS LIMITED  
Ahmedabad

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SHUKRA PHARMACEUTICALS LIMITED** (the "Company"), for the quarter and half Year ended September 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.






4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For MAAK and Associates**

[Firm Registration No.135024W]


Chartered Accountants



Marmik Shah

Partner

Mem. No. 133926



Place: Ahmedabad

Date: 14<sup>th</sup> November, 2024

UDIN: **24133926BKCKDO5081**